Company Overview and News

22
Your Cancer Highlight: AbbVie Quietly Aims For A New Best-In-Class Approval In CLL

5h seekingalpha
The implications for CLL management are clear, and they signal a tighter weaving of one of their main drugs into the standard of care.
JNJ ABBV ABBV

10
Why Gilead Stock Is a Sleepy Giant Waiting to Break Out

9h investorplace - 1
Gilead Sciences (NASDAQ:GILD) stock is stuck in a range and for good reason. The markets cannot decide if its quarterly revenue declines are permanent or if the company’s growth is reaccelerating again. Yet if investors hold Gilead stock and collect its 3% dividend yield, they will get an even bigger reward if two things happen.
GILD ABBV ABBV

18
Intercept And NASH: Itching To The Finish Line

14h seekingalpha
Ocaliva is a Farnesoid X receptor agonist that positively regulates glucose, lipid and bile homeostasis and was the first FDA approved therapy for primary biliary cirrhosis in over two decades.
ENTA SGYP CELGZ JUNO CNAT CELG SGYPW NVS ABBV ICPT

11
Pfizer's Skin Disease Candidates Positive in Mid-Stage Study

18h zacks - 1
Pfizer Inc. (PFE - Free Report) announced positive top-line data from a phase IIa study evaluating its JAK3 inhibitor candidate, PF-06651600, and tyrosine kinase 2/JAK1 inhibitor, PF-06700841, as a treatment for moderate to severe alopecia areata (“AA”).
PFZ ACRS ABBV 500680 PFE PFIZER ABBV

9
ABBV / AbbVie Inc. 424B5 (Prospectus)

2018-09-17 sec.gov
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS
ABBV

20
The Zacks Analyst Blog Highlights: JPMorgan, Mastercard, AbbVie, CVS Health and Estee Lauder

2018-09-17 zacks
Chicago, IL – September 17, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include JPMorgan (JPM - Free Report) , Mastercard (MA - Free Report) , AbbVie (ABBV - Free Report) , CVS Health (CVS - Free Report) and Estee Lauder (EL - Free Report) .
MA ABBV CVS ABBV

245
Stocks To Watch: Oracle Looks To Lift Tech Sector

2018-09-15 seekingalpha - 3
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
DOVA GIS TXN CAT AZO TWX RCL OPRF MAS HABT SHAK SUM BOX SONC RCII ABBV USCR FOX REGN BAC SQ DFS TRV COF-P WK BX JACK SYF AIG WEN ALL IDA KNSA NVS ABBV MSFT FL ZOES PFE ADS FOXA MLM JD NIO ATH DRI CX PYPL AXP MCO JBHT BRO EXP USB BAC COF-D COF-C COF-F HIG AAPL VMC TSG ORCL DEO MCD BMY RRGB WBC C CMCSA O THO MA M COF FDX NAVG HUM SNY RHT DSKE JPM IBOC MU DHR

29
Top Stock Reports for JPMorgan, Mastercard & AbbVie

2018-09-14 zacks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including JPMorgan (JPM), Mastercard (MA) and AbbVie (ABBV). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
STQN MA CVS BRK.A KMI ABBV OXY KMR KMRFZ CVB ABBV

25
Pharma/Biotech Stocks to Watch This Prostate Cancer Month

2018-09-14 zacks - 1
September is observed as National Prostate Cancer Month to raise awareness about the disease, which is the leading cause of death in men, second only to skin cancer in the United States. A light blue ribbon is used as a symbol to raise awareness about prostate cancer.
4503 TSRO ALPMY AZN ECYT CY ALPMF AZN ABBV PFE ABBV SNY

23
Roche's Child Arthritis Drug's New Formulation Gets FDA Nod

2018-09-14 zacks
Roche Holding AG’s (RHHBY - Free Report) subsidiary, Genentech announced that the FDA has approved a label expansion for its arthritis drug, Actemra. The FDA approved a subcutaneous (SC) formulation — a prefilled syringe that can be injected at home —of Actemra for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients aged two years or older.
RHHVF CY RHHBY ABBV GM ABBV RHHBF

9
ABBV / AbbVie Inc. FWP

2018-09-14 sec.gov
Filed pursuant to Rule 433 Dated September 13, 2018
ABBV

46
Your Daily Scoop: Foamix Zooms, Pfizer And Merck Report Positive

2018-09-13 seekingalpha
Share price of Foamix Pharmaceuticals (FOMX) had a 54.4% spike on September 11 after-hours on the news of positive topline results of third Phase 3 clinical trial of its FMX101 drug. The candidate is indicated in the treatment of moderate-to-severe acne. The trial is reported to have successfully met both primary and secondary endpoints.
MKGAF OPK GILD INCY KMPH GLPG ACRX IMNP MKGAY NVS ABBV FMI PFE ABBV FOMX

26
Short Sellers Back Off Major Pharma Stocks

2018-09-13 247wallst
Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study come back negative or a candidate not be approved. Conversely, if a drug gains FDA approval or passes a clinical trial, there can be big upside.
PFZ TEVJF MRK TEVA TEVVF ABBV LLY 500680 PFE PFIZER ABBV BMY

10
Should Value Investors Consider AbbVie (ABBV) Stock Now?

2018-09-13 zacks
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value? One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process.
BLL ABBV ABBV

9
ABBV / AbbVie Inc. 424B5 (Prospectus)

2018-09-13 sec.gov
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS
ABBV

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

10h - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

11h - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

13h - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 00287Y109